Investigational drug · Phase 2
KAE609
Also called: Cipargamin
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Uncomplicated Plasmodium Falciparum Malaria, Severe Malaria.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
5
2 still active
All registered trials
12
Any phase or sponsor naming "KAE609"
First trial start
2022
Mar 7, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KAE609", any sponsor or status.
Conditions studied
As listed on its trial records.
- Uncomplicated Plasmodium Falciparum Malaria
- Severe Malaria
Approved drugs for the same conditions: Malaria · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "KAE609" as an intervention, largest first.
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum MalariaPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05750628 · 327 participants (planned) · Start Jan 23, 2024 · Primary completion Jun 9, 2026
Drug: INE963; KAE609 (Cipargamin) and 2 more · For: Uncomplicated Plasmodium Falciparum Malaria
Sites: Banfora, Burkina Faso; Nanoro, Burkina Faso; Abidjan, Côte d’Ivoire · 12 sites in all
- To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum MalariaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04675931 · 254 participants · Start Mar 7, 2022 · Primary completion Jul 24, 2025
Drug: Cipargamin; IV Artesunate and 1 more · For: Severe Malaria
Sites: Burkina Faso, Burkina Faso; Ouagadougou, Burkina Faso; Abidjan, Côte d’Ivoire · 9 sites in all
- Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03334747 · 188 participants · Start Nov 16, 2017 · Primary completion Nov 23, 2019
Drug: KAE609; Coartem · For: Malaria
Sites: Lambaréné, Gabon; Kintampo, Ghana; Navrango, Ghana · 9 sites in all
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07811908 · 120 participants (planned) · Start Feb 12, 2026 · Primary completion Feb 4, 2027
Drug: KAE609; SoC (Coartem) and 1 more · For: Uncomplicated Plasmodium Falciparum Malaria
Sites: Banfora, Burkina Faso; Nanoro, Burkina Faso; Abidjan, Côte d’Ivoire · 13 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07811882 · 95 participants · Start Oct 10, 2025 · Primary completion Jun 17, 2026
Drug: KAE609 (Cipargamin); SoC (Coartem) and 1 more · For: Uncomplicated Plasmodium Falciparum Malaria
Sites: Banfora, Burkina Faso; Nanoro, Burkina Faso; Abidjan, Côte d’Ivoire · 13 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07235033 · 60 participants · Start Jan 23, 2024 · Primary completion Mar 5, 2025
Drug: KAE609; SoC (Coartem) and 1 more · For: Uncomplicated Plasmodium Falciparum Malaria
Sites: Abidjan, Côte d’Ivoire; Libreville, Gabon; Ahero, Kenya
Novartis PharmaceuticalsNovartis (NVS)
NCT04321252 · 57 participants · Start Jul 22, 2020 · Primary completion Nov 10, 2020
Drug: KAE609; Placebo · For: Malaria
Sites: Antwerp, Belgium
Novartis PharmaceuticalsNovartis (NVS)
NCT01524341 · 27 participants · Start Jan 2012 · Primary completion Jun 2012
Drug: KAE609 · For: Malaria
Sites: Bangkok, Thailand; Tak, Thailand; Tak Province, Thailand
Novartis PharmaceuticalsNovartis (NVS)
NCT01836458 · 25 participants · Start Jan 2014 · Primary completion Mar 2015
Drug: KAE609 · For: Malaria
Sites: Ho Chi Minh City, Vietnam
Medicines for Malaria VentureAcademic, hospital or other
NCT02867059 · 17 participants · Start Sep 13, 2016 · Primary completion Dec 22, 2016
Drug: (+)-SJ000557733 · For: Plasmodium Falciparum Malaria
Sites: Brisbane, Australia; Herston, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Antimalarial efficacy of isatin and oxindole derivatives: A comprehensive update.
Thakur RK, Patel OPS · Eur J Med Chem 2027
- TRIDENTߛX: A Reproducible R Protocol for Comparative Systems Pharmacology and Target Deconvolution from DualߛCompound TimeߛCourse Transcriptomics (KAE609 vs. PA21A092).
George OA, Igunnu A, Adebayo JO · Curr Protoc 2026
- Thermal Proteome Profiling Identifies New Drug Targets in Plasmodium falciparum Parasites.
Pazicky S, Dziekan JM, Tjia S, et al. · Mol Cell Proteomics 2026
- Targeting Biofilm Formation in Acinetobacter baumannii: In Silico Discovery of Novel Candidate Inhibitors for Acyl-Homoserine Lactone Synthase.
Singh T, Singh RP, Jain M, et al. · Curr Drug Discov Technol 2026
- Assessment of the pharmacodynamic properties of antimalarial drugs.
White NJ · Philos Trans R Soc Lond B Biol Sci 2026
- Validation of solvent proteome profiling for antimalarial drug target deconvolution.
Ji Y, Morrow JP, MacRaild CA, et al. · Int J Parasitol Drugs Drug Resist 2025
Also in development for Uncomplicated Plasmodium Falciparum Malaria
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.